Rachel A. Freedman, MD
About 50% of patients with metastatic HER2-positive breast cancer will eventually develop central nervous system (CNS) metastases at some point in their treatment course.
, lead study author Rachel A. Freedman, MD, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, discussed treating patients with HER2-positive breast cancer who develop CNS metastases, and the promise that neratinib holds in this patient population.
OncLive: Can you provide an overview of this study of neratinib and capecitabine in HER2-positive breast cancer?
Patients with HER2-positive breast cancer that is metastatic have a high likelihood of developing CNS metastases. Many women will continue to progress in their CNS after local therapies are administered, such as radiation and surgical therapies. It is a real unmet need for our patients, and many patients end up dying of their CNS disease over time.
... to read the full story